학술논문
180TiP Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial
Document Type
Abstract
Author
Source
In Annals of Oncology May 2020 31 Supplement 2:S80-S81
Subject
Language
ISSN
0923-7534